Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:53:24.450Z.
Calculation as of: 2026-10-06T21:53:24.450Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 91899883c476d55b2433093e583c87952940339a9b77bc55d8a3dd78c9ec7759
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$953.81M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$934.79M
Operating Cash Flow Yield
N/A
TTM Avg
16.88%
3Y Avg
16.91%
5Y Avg
16.91%
Market Cap
$973.93M
Operating Cash Flow Yield
19.27%
TTM Avg
14.96%
3Y Avg
15.37%
5Y Avg
11.65%
Market Cap
$929.83M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$978.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Operating Cash Flow Yield
1.39%
TTM Avg
0.99%
3Y Avg
0.99%
5Y Avg
0.99%
Market Cap
$982.46M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Savara Inc. (SVRA) | $952.91M | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $934.79M | N/A | 16.88% | 16.91% | 16.91% |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 19.27% | 14.96% | 15.37% | 11.65% |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $929.83M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 1.39% | 0.99% | 0.99% | 0.99% |
| CeriBell, Inc. (CBLL)vs › | $923.53M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| MoonLake Immunotherapeutics (MLTX)vs › | $921.06M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
